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the limited contact of only a fraction of the applied vector
dose with the target cells represents a major limitation to
successful and efficient nucleic acid delivery. As a conse-
quence, physical methods that accelerate vector parti-
cles toward the target cells have been successful in en-
hancing nucleic acid delivery. These methods include
exploiting gravitational (Luo and Saltzman, 2000) or cen-
trifugal force (Bunnell et al., 1995) which sediment parti-
cles on the cells and which are proportional to particle
mass. Also convective flow of the transfection medium
toward the target cell is a useful tool to enhance gene de-
livery (Chuck et al., 1996). Furthermore,these methods in-
clude biolistic methods (the ‘gene gun’ approach; Klein
et al., 1992) and the application of electric fields (‘electro-
poration’, for a review see Somiari et al., 2000). Not sur-
prisingly, one of the earliest nonviral gene delivery meth-
ods exploited gravity by the formation of precipitates
from DNA and calcium phosphate (Chen and Okayama,
1988). Also with modern synthetic gene transfer systems,
large and/or heavy vector particles were more efficient in
gene delivery than small particles (Ogris et al., 1998; Luo
and Saltzman, 2000). In addition to the mentioned bio-
physical barriers, also insufficient targetability of nucleic
acid vectors to target cells/organs represents a limitation
to their use in therapy or as research reagents. In the one
extreme, limited targetability is due to the lack of a spe-
cific target cell tropism and as a consequence systemic
spread of the vector if applied in vivo, limited bioavailabil-
ity at a desired target site and the possibility of non-spe-
cific transfection of non-target cells/organs. In the other
extreme, a very specific host tropism can limit the appli-
cability of a vector to a broader target spectrum. This
problem prevails for some viral vectors, both in ex- and in
vivo gene delivery (Kim et al., 2002). A further limitation
can be the rapid inactivation of vectors due to undesired
interactions with components of the in vivo milieu before
the vector can find its target site. Examples of undesired
interactions are opsonization of nonviral vectors (Ogris
et al., 1999) or interactions of vectors with host defense
systems such as the complement (Plank et al., 1996) or
the immune system (Kass-Eisler et al., 1996). Hence,
there is an urgent need for simple, affordable and efficient
tools for rapid accumulation of gene vectors at their tar-
get sites. It would be most desirable if vector accumula-
tion could be remotely controlled by physical means, par-
ticularly in the case of intravenous or other systemic
administration in vivo.
We have recently developed a method of magnetically
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In order to enhance and target gene delivery we have
previously established a novel method, termed mag-
netofection, which uses magnetic force acting on
gene vectors that are associated with magnetic parti-
cles. Here we review the benefits, the mechanism and
the potential of the method with regard to overcom-
ing physical limitations to gene delivery. Magnetic
particle chemistry and physics are discussed, fol-
lowed by a detailed presentation of vector formula-
tion and optimization work. While magnetofection
does not necessarily improve the overall perform-
ance of any given standard gene transfer method in
vitro, its major potential lies in the extraordinarily rap-
id and efficient transfection at low vector doses and
the possibility of remotely controlled vector targeting
in vivo.
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Introduction
Nucleic acid delivery to cells in culture is to a large extent
a diffusion-limited process if the nucleic acid shuttle (the
vector) is of nanometric size, which is the case for virus-
es (Chuck et al., 1996) and many synthetic systems.
Hence, apart from the major biological barriers including
the plasma, endo/lysosomal and nuclear membranes,
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targeted nucleic acid delivery which we call magnetofec-
tion (Scherer et al., 2002): vectors are associated with su-
perparamagnetic nanoparticles and accumulated on the
target cells by the application of magnetic gradient fields
(Figure 1, principle of magnetofection). We have shown
that this approach is equally applicable to viral as well as
nonviral gene vectors and that it potentiates and targets
gene delivery in vitro as well as in vivo (Scherer et al.,
2002). Our approach is based on previous work with low
molecular weight drugs, mostly cytostatics, which, asso-
ciated with magnetic particles, were accumulated in tu-
mors and other tissues by the application of appropriate
magnetic fields (Gupta and Hung, 1993; Lübbe et al.,
1996; Lübbe and Bergemann, 1997, 1998; Alexiou et al.,
2000). Other approved medical applications of magnetic
particles include their use as contrast agents in magnetic
resonance imaging, so that the pharmacokinetics and
toxicity profiles of certain classes of iron oxide particles
are well described (Weissleder et al., 1989). Pioneering
work by Weissleder and coworkers has produced multi-
ple applications of the technique, among these also im-
aging of transgene expression (Lewin et al., 2000;
Weissleder et al., 2000; Wunderbaldinger et al., 2000).
Magnetic Particle Chemistry and Physics
The particles used in such approaches were mostly iron
oxides, the synthesis of which is described mainly in the
patent literature (see for example Pilgrimm, 1999) but
also in text books (Schwertmann and Cornell, 1991).
Briefly, such particles are derived by precipitation from
acidic iron(II)/iron(III)-salt solutions upon addition of
bases. Notably, also particles consisting of double ox-
ides/hydroxides of two- or three valent iron with metal
ions from the first row of transition metals, such as Co(II),
Mn(II), Cu(II), Ni(II) or Cr(III), Gd(III), Dy(III), Sm(III), and fur-
thermore finely milled metallic materials display the char-
acteristics that make them suitable as magnetic carriers.
To stabilize such particles they are coated with polymers,
for use in biology preferably with biocompatible polymers
of synthetic or natural origin. It is important to note that
chemists were not the first to design such particles. Mag-
netite crystals are found in living organisms such as mag-
netotactic bacteria, in the central nervous systems of fish
and even in the human brain (Kirschvink et al., 1992;
Mertl, 1999; Diebel et al., 2000; Lohmann and Johnsen,
2000). At least for fish, magnetite has been defined as a
magnetoreceptor essential for orientation along the
earth’s magnetic field (Diebel et al., 2000), and there is ex-
perimental evidence that similar mechanisms apply in mi-
gratory birds (Beason et al., 1995).
The term ‘magnetic particle’ used in the literature and
also here generally refers to magnetically responsive sol-
id phases, which are particles or aggregates thereof with
micro- to nanometer size. The often used, but physically
unprecise term ‘magnetic’, refers to temporarily magnet-
ic materials, which can be ferrimagnetic or ferromagnet-
ic. The term, however, also comprises paramagnetic and
superparamagnetic materials. For the precise meaning of
these terms the reader is referred to Fahlvik et al. (1993)
or to text books of physics. The important characteristics
for the application described here are that magnetic par-
ticles would orient in an externally applied magnetic field,
an orientation (magnetization) that however would be im-
mediately overcome by thermal motion upon removal of
the external field. In order to have the particles move in a
preferred direction of space, they must ‘sense’ an inho-
mogenous magnetic field (‘gradient field’). The magnetic
force acting on such particles in a liquid suspension is
proportional to the particle volume, to the magnetic flux
density and the magnetic field gradient (Zborowski et al.,
1995). This relationship sets the framework that any us-
age of such particles has to cope with.
Magnetofection – Magnetic Particles in Gene
Delivery
The conclusion that what is feasible with low molecular
weight compounds should work for nucleic acids as well
may appear trivial, however the implementation of such
an approach requires a careful consideration of critical
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Fig. 1 Principle of Magnetofection.
Vectors and magnetic particles are associated by an appropriate
linkage, in our case by salt-induced colloid aggregation (see Fig-
ure 2). For this purpose, magnetic particles were coated with
polyelectrolytes, i.e. the polyelectrolyte is tightly bound to the
particle surface. In most of the experiments shown here, poly-
ethylenimine (PEI) was used as coating polyelectrolyte. If such
particles are mixed with naked DNA, lipoplexes or polyplexes
(such as PEI-DNA) in salt-containing buffer they will bind to or
co-aggregate with these compounds. Cells are incubated with
the vector-magnetic particle cocktail under the influence of a
magnetic field which attracts the particles toward the cells. We
have constructed magnetic plates from Nd-Fe-B permanent
magnets (Scherer et al., 2002). The result of magnetofection is
that essentially all cells get in contact with vectors and a high
percentage of cells are rapidly transfected.
parameters: nucleic acids are charged macromolecules
(polyelectrolytes) with their own very peculiar biophysical
characteristics (Bloomfield, 1996). Unlike many low mo-
lecular weight drugs, they cannot cross the cellular mem-
branes by simple diffusion, and if genes are to be deliv-
ered in the form of DNA, the molecules have to reach the
nuclei of target cells. Hence, natural transport processes
such as endocytosis have to be exploited to deliver these
molecules, which holds also true if viruses are used as
the nucleic acid shuttle. This means that the association
of the vectors with magnetic particles must not interfere
with the transport processes used. At the same time, the
association has to be stable enough to endure the deliv-
ery process itself which in vivo involves interactions with
host defense mechanisms and a multitude of solutes in
blood and other body fluids. All this imposes certain re-
quirements on the physical nature (size and surface char-
acteristics) of the transport system as a whole, but also of
its components, and also on the linkages that hold the
components together. Provided that magnetic particles
with appropriate reactive surface groups are available,
physical, chemical and biological linkages can be envis-
aged. Among the latter, biotin-streptavidin and antigen-
antibody bridges have been successfully used to link
viruses to nonviral vector particles (Curiel et al., 1991;
Wagner et al., 1992) and more recently also to link virus-
es to magnetic particles (Hughes et al., 2001; Mah et al.,
2002; Pandori et al., 2002). The term nonviral vector par-
ticle refers to complexes of DNA with polycations (‘poly-
plexes’) or cationic lipids (‘lipoplexes’). These complexes
have been shown by numerous researchers to be parti-
cles of nanometric size or aggregates thereof. Often,
toroids and rods are observed for polyplexes and less
regular structures for lipoplexes, sometimes extending
into the micrometer size range (an example of such struc-
tures is shown in Finsinger et al., 2000). As (strept)avidin
or antibody-coated magnetic particles are expensive to
manufacture, we decided to use the simplest way of link-
age, physical interaction, which not only is the cheapest
way but also highly effective and fully compatible with the
cellular processing of gene vectors. Therefore we used
magnetic particles coated with polyelectrolytes (in the
following often referred to as ‘magnetic particles’) which
are, in the same manner as many nonviral vector parti-
cles, subject to salt-induced aggregation (Figure 2A), a
phenomenon well known in colloid science (Hiemenz,
1986). In this manner, simple mixing of polyelectrolyte-
coated magnetic particles and gene vectors at an appro-
priate ratio in salt-containing medium was sufficient to
achieve quantitative association (Scherer et al., 2002). It
is important to note that when pre-assembled nonviral
vectors are associated with polyelectrolyte-coated mag-
netic particles, the vector and the magnetic particles do
not need to have opposite surface charges. In fact, in
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Fig. 2 Vector Association with Magnetic Particles: Salt-Induced Colloid Aggregation.
(A) A ternary complex was prepared in water by mixing DNA with PEI-coated magnetic particles and additional free PEI (10 µg DNA/ml
final concentration; 25 kDa PEI from Aldrich). Salt-induced aggregation was initialized by adjusting the ionic strenght to 150 mM sodi-
um chloride. The complex aggregated with approx. linear kinetics starting at 217.0±2.0 nm and remaining in the sub-micrometer range
within two hours (size measurement by dynamic light scattering using a Malvern 3000 HS Zetasizer). (B) Electron microgaphs of PEI-
coated magnetic particles (transMAG-PEI, left) and their associates with PEI-DNA vectors produced by salt-induced aggregation (right)
as described in (A). The micrographs show that the magnetic particles are multi-domain structures of irregular shape. The resulting DNA
complexes (right) display a tight association of PEI-DNA structures (gray/black spherical structures) with magnetic particles. Electron
microscopy was performed as described by Erbacher et al. (1999). (C) DNA binding isotherms. DNA was labeled with [125I] according to
the Commerford method modified as described by Terebesi et al. (1998). DNA (squares) or PEI-DNA complexes (circles; N/P ratio=8)
were mixed with magnetic particles in water at increasing particle:DNA weight ratios, final DNA concentration 10 µg/ml. The N/P ratio
is the ratio of the nitrogen atoms of PEI to the phosphate groups of DNA in the complex. In water (open squares and circles) magnetic
particles did not associate with PEI-DNA complexes but bound naked DNA. Upon adjustment of the ionic strength to 150 mM sodium
chloride, binding of naked DNA was enhanced up to 1.7-fold at a given weigth ratio. A sigmoidal binding curve was obtained for PEI-
DNA. The binding curves demonstrate the importance of salt-induced aggregation for vector-particle association and show that posi-
tively charged magnetic particles can easily be associated with positively charged gene vectors. Interestingly, PEI-DNA vectors dis-
played a similar binding behaviour with negatively charged magnetic particles (data not shown).
most of our experiments we associated positively
charged vector particles with positively charged magnet-
ic particles (Figure 2). The appropriate ratios of magnetic
particle and vector (or naked DNA) were found by serial
titrations of radiolabeled DNA with magnetic particles fol-
lowed by magnetic sedimentation and determination of
the DNA fraction remaining in the supernatants (Fig-
ure 2B). The binding data were then set in correlation to
gene transfer efficiency data obtained with multi-dimen-
sional titrations of vector dose/magnetic-particle-to-DNA
ratios/vector type in various standard cell lines. From
such titrations we found numerous examples where
magnetofection was clearly superior to standard trans-
fection with the same vector (some examples are shown
in Figures 6 – 9 and in Scherer et al., 2002). However,
there were also examples where magnetofection was su-
perior only in some but not all aspects. Figure 3 shows
such an example with the lipofection reagent GenePorter
(from Gene Therapy Systems, Inc., San Diego, USA)
which is shown here because it highlights benefits and
limitations of magnetofection in a single experiment.
CHO-K1 cells were transfected in the 96-well format with
serial dilutions of vector compositions containing zero
(standard vector) or increasing amounts of magnetic par-
ticles. The incubation times were either 10 minutes or
4 hours with or without exposure to a magnetic field, fol-
lowed by washing of the cells. Figure 3A versus 3B shows
the strong enhancement of transfection by the influence
of the magnetic field during short time incubation and the
failure of the standard vector to yield significant transfec-
tion levels during this short time. High magnetic particle
content led to a drop in transfection efficiency. The drop
was particularly pronounced at the higher DNA doses,
probably due to toxicity. Comparing Figures 3A and B to
3C and D shows that magnetofection achieved the same
order of magnitude of transgene expression level within
10 minutes of incubation as achievable within 4 hours (al-
though an approximately 4-fold increase was obtained
during 4 hours of incubation). Comparing Figure 3C and
D shows first of all that long time exposure to the mag-
netic field did not yield major enhancements. In fact, de-
pending on the exact vector composition and dose, the
transfection without magnetic field was superior in some
instances. Another important lesson from this experiment
was that magnetofection of a cell line in vitro is not nec-
essarily superior to the standard procedure in terms of
the achievable overall transgene expression level. A
close look at Figures 3C and D reveals that the standard
transfection procedure was outdone by magnetofection
only at the lower vector doses. Taken together, results
shown in Figure 3 indicate that magnetofection is rapid in
achieving very significant transfection levels, but that it
requires fine tuning of vector choice, vector composition,
vector dose and incubation time to exceed the overall ex-
pression levels obtained with some standard methods
during long-time incubation.
It was an interesting finding that the mixing order of the
vector components (DNA, polyelectrolyte-coated mag-
netic particles, third components such as cationic lipids
or polyethylenimine) did not have a major influence on the
observed transfection efficiencies. Neither was there a
major difference in dependence on whether the surface
coating of the magnetic particles was polycationic or
polyanionic (an example is shown with the lipofection
reagent DOTAP-cholesterol in Figure 4). Also, the trans-
fection efficiency was largely independent of the type of
polycation or polyanion used for particle coating (data
not shown). Various coatings including PEI of various mo-
lecular weights, DEAE dextran, poly(aspartic acid),
poly(maleic acid), poly(acrylic acid), or phosphate-de-
rivatized starch were tested. This formulation work led us
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Fig. 3 Dose-Response Profiles of Magnetofection of CHO-K1
Cells with the GenePorter Reagent.
One vol. equivalents of DNA stock solutions in DMEM (20 µg/ml)
were added to equal volumes each of a serial dilution of mag-
netic particles in DMEM, mixed, and then mixed immediately
with two vol. equivalents GenePorter dilution (50 µl/ml in
DMEM). The samples were diluted with DMEM to a volume cor-
responding to 20 vol. equivalents, then a series of two-fold dilu-
tion steps in DMEM was performed in a 96-well plate. The medi-
um from cells that were seeded in 4 plates at a density of 20 000
cells/96 well was removed and 100 µl each of DNA complexes
were added in triplicates. Two plates each were incubated as
usual and two plates each on a magnetic plate for 10 min and
4 hours, respectively. The 10 min incubation plates were washed
and then supplemented with fresh medium containing 10% FCS
and penicilllin/streptomycin. To the 4 hour plates 100 µl/well of
fresh medium containing 20% FCS (+ pen/strep) were added
without a washing step. The luciferase assay was carried out as
described (Finsinger et al., 2000) after 24 hours. The Figure
shows that the transfection efficiency decreased at higher mag-
netic particle doses probably due to toxicity. A magnetic particle
to DNA ratio of 4 turned out useful at all DNA doses. The data
points represent the averages of triplicates ± standard devia-
tions.
to a simple protocol of magnetic vector formulation and
application: the gene vector is prepared as usual with
commercially available reagents according to the instruc-
tions of the manufacturer. In an additional step, the pre-
formed vector is then mixed with an amount of magnetic
particles such that the weight/weight ratio of magnetic
particles and DNA will be 1:1 and higher. After an incuba-
tion time of 15 to 30 min, the magnetic vectors are added
to the cells in standard culture plates which are posi-
tioned on a magnetic plate (Scherer et al., 2002) for
15 minutes. After this time, the medium can either be
changed or left on the cells until further evaluation (such
as luciferase assay etc.). Magnetic plates for transfection
purposes are commercially available (chemicell, Berlin,
Germany) but can also be home-made with strong per-
manent magnets (Scherer et al., 2002). Similar plates are
available mostly for cell or nucleic acid separation pur-
poses from a number of suppliers (including Dexter,
Promega, Miltenyi, Dynal) and may be useful for mag-
netofection, depending on the geometry of the magnet
positioning. The essential requirement for magnetofec-
tion is that the magnetic particle-associated vectors ex-
perience a magnetic gradient field strong enough to pull
them toward the cells to be transfected. As the fields of
individual magnets in close proximity will influence each
other, it is difficult to achieve an even distribution of mag-
netically sedimented vectors on the cells. On the other
hand, with an appropriate positioning of magnets, it is
easy to obtain a selective transfection of only part of a
cell population within one well (Pandori et al., 2002;
Scherer et al., 2002). While this already demonstrates the
principle possibility of selective magnetic field-directed
targeting for in vivo gene delivery, this feature may also be
a useful technical tool for evaluating gene or protein func-
tion having the untransfected cell control within the same
well.
Mechanism and Benefits of Magnetofection
The major efficacy-enhancing mechanism of magneto-
fection appears to be the rapid sedimentation of the full
vector dose on the target cells, such that up to 100% of
these cells will have vector particles bound to their sur-
faces within a few minutes (see for example Figure 9).
Achieving the same frequency of vector-target cell con-
tact may take hours during conventional transfection.
Nevertheless, an additional effect of the magnetic field
can not be excluded. It has been shown that upon injec-
tion of magnetic particles into rat tail veins and position-
ing of a strong permanent magnet downstream of the in-
jection site, magnetic particles are found outside the
blood vessel, implying that the magnetic field had caused
extravasation into the surrounding tissue (Gupta and
Hung, 1993). Therefore, it can be speculated that the
magnetic field might pull the magnetic particle-vector as-
sociates across the plasma membrane into the cells.
Also, as of yet unknown changes in cellular physiology
upon exposition to the magnetic field may play a role.
However, our results indicate that the primary uptake
mechanism proceeds via the endo/lysosomal pathway,
as we have argued before (Scherer et al., 2002). With
naked DNA bound by electrostatic interaction to polyca-
tion-coated magnetic particles we only achieve low
effiency gene transfer. When to this associate PEI,
cationic lipids, a membrane-destabilizing agent such as
the peptide INF7 (Plank et al., 1994) or an inactivated
adenovirus (Cotten et al., 1994) are added, gene delivery
is greatly enhanced. All these agents have been inferred
to mediate endo/lysosomal release upon endocytotic
vector uptake and therefore to enhance the transfection
efficiency. Another strong evidence of endosomal uptake
comes from electron microscopic studies that we have
carried out (Figure 5). We found magnetic particles asso-
ciated with a majority of the cells within 15 min of mag-
netic field exposure. We found particles in cellular invagi-
nations resembling coated pits (Figure 5A). After 24 hours
we often found the particles in membrane-surrounded
structures which may be endosomes or lysosomes (Fig-
ure 5B). When the DNA component was labeled with col-
loidal gold, we found co-localization of magnetic parti-
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Fig. 4 Magnetofection of NIH 3T3 Cells Using the DOTAP-
Cholesterol Reagent and Magnetic Particles with Positive and
Negative Surface Charges.
DOTAP (1,2-dioleoyl-3-trimethylammoniumpropane) was pur-
chased from Avanti Polar Lipids (Alabaster, AL, USA). DOTAP/
cholesterol (molar ratio 1:0.9) liposomes were prepared essential-
ly as described (Meyer et al., 1995) as 5 mM (DOTAP) suspension
in 5% glucose. Two mixing protocols were used. (,): one vol.
equivalent DNA stock solution in HBS (30 µg/ml) was mixed with
one vol. equiv. DOTAP/chol liposome stock (455 µM DOTAP in
HBS) followed by mixing with one vol. equiv. magnetic particle
suspensions (30 µg/ml). (,): using the same reagents, first
magnetic particles and DNA were mixed and then added to
DOTAP-chol. Magnetic particles were transMAG-PO4 (coating
with phosphorylated starch), transMAG-PEI (coating with PEI). A
dilution series was prepared to yield the indicated DNA doses per
well (50 µl aliquots of DNA complexes were added per well in trip-
licates). Cells were seeded 7 hours prior transfection at a density
of 30 000 cells/well in 150 µl DMEM/10% FCS/pen,strep. Per set-
up, experiments were carried out with (full symbols) and without
positioning on a magnetic plate (open symbols) during 10 min of
incubation followed by medium change.
pression and incubation time of cells with the vector
cocktail. The same experiment carried out with Lipofect-
amine (Figure 6A and C) resulted in even decreasing
transfection efficiency with increasing incubation time in
the case of magnetofection, while the standard vector
displayed a minor linear increase but being rather ineffi-
cient overall. Taken together, the transfection kinetics is
another indication that the major enhancing factor in
magnetofection is the rapid accumulation of the full vec-
tor dose at the target cell surface. This also led to a very
early onset of reporter gene expression (as shown in Fig-
ure 7 for PEI-DNA complexes). Within 2 hours after a
15 minute magnetofection period, significant reporter
gene expression levels were detectable, while it took be-
tween 4 and 8 hours to reach the minimal detectable ex-
pression level by standard transfection. For some vec-
tors, another beneficial consequence of the rapid cell
binding of the full vector dose was the highly favorable
dose-response profile of magnetofection compared to
standard transfection. For example, logarithmic profiles
were observed for magnetofection with PEI, DOTAP-
Cholesterol or Lipofectamine in contrast to a linear profile
for standard transfection (Figure 4, DOTAP-Cholesterol;
Figure 6, Lipofectamine). This means that by applying
magnetofection, high transgene expression levels can be
achieved at a very low vector dose with extremely short
incubation times. This allows avoiding toxicity with cells
that are sensitive to the transfection process (Krötz et al.,
2003). High transgene expression levels are either
achieved by having a few cells expressing tremendous
amounts of the transfected gene or by having a high per-
centage of target cells transfected. In most of our mag-
netofection experiments we observed a combination of
both, a high percentage of transfected cells producing
high amounts of transgene product (as shown in Figure 8
for CT26 colon carcinoma cells transfected with DMRIE-
C and as also shown in Scherer et al., 2002, for adenovi-
ral and retroviral magnetofection). Despite this success it
needs to be emphasized that the final transgene expres-
sion level achieved with magnetofection is not necessar-
ily higher in all cases than the one achieved under opti-
mized conditions with a given standard transfection
protocol (as is also evident from Figures 3 and 6). Like
with all gene delivery methods, this is dependent on the
cells to be transfected and on the skills and the aware-
ness of the experimentator. In summary, the benefits of
magnetofection are that (i) it saves time, (ii) it saves mate-
rial, (iii) it can potentiate the efficacy of a given vector, and
(iv) it allows magnetic field-guided targeting.
Applications of Magnetofection
These features make magnetofection a very useful tool
where any one or several of these key points limit the
success of a given approach involving nucleic acid deliv-
ery. There are multiple examples of such technical chal-
lenges: from gene therapy, where nucleic acid delivery it-
742 C. Plank et al.
Fig. 5 Electron Micrographs of Magnetic Particle Complex
Uptake in HeLa Cells.
HeLa cells were seeded in 35 mm dishes at a density of 300 000
cells/well on the day prior transfection. Magnetic particle-DNA
complexes were prepared at a particle:DNA ratio (w/w) of 2
(4 µg/ml final DNA concentration in 5% glucose). The magnetic
particle type used here were multi-domain iron oxide core coat-
ed with a multilayer of polyethylenimine (800 kDa, Fluka). Cells
were kept in 1 ml of medium, dishes placed on the magnetic
plate, 250 µl DNA complex were added and incubated for
15 min. Cells were then washed gently and fixed in Sorensens
buffer containing 1% glutaraldehyde for one hour, washed
again, post-fixed in 1% aqueous osmium tetroxide, washed,
and subjected to a dehydration series in graded ethanols. The
samples were embedded in Epon. After sectioning, the samples
were counter-stained with uranyl acetate and lead citrate. (A)
Sample prepared directly after 15 min of magnetofection. (B)
Sample prepared after 15 min magnetofection and 24 hours of
further incubation. The pictures show endocytotic uptake of
magnetic particle-DNA complexes. After 24 hours particles are
frequently found inside cells, often in membrane-surrounded
structures and even in the nucleus.
cles and DNA within the cells (data not shown). When we
examined the influence of the duration of magnetic field
exposure during magnetofection on the final transfection
efficiency after 24 hours, we found that the mechanisms
responsible for the observed high transfection efficien-
cies act during the first minutes of the magnetofection
process. This is apparent from an experiment carried out
with NIH 3T3 cells and the lipofection reagents Lipofect-
amine and GenePorter (Figure 6). For GenePorter-DNA
associated with magnetic particles, exposing the cells to
the vector under magnetic field influence only for five
minutes was sufficient to yield 42% of the transfection
level observed upon 4 hours of incubation, after 40 min
already 73% of this level were reached, while 5 min stan-
dard transfection with the magnetic particle-free parent
vector yielded only 0.04% and 4 hours yielded 20%, re-
spectively, of the reporter gene expression level achieved
with magnetofection during 4 hours. For GenePorter, the
kinetics of the magnetofection process displayed a loga-
rithmic profile, while the process with the same vector in
the absence of a magnetic field or with the standard vec-
tor displayed a linear relationship between luciferase ex-
self is at the heart of the therapeutic strategy, to basic re-
search or even commercial scale biotechnology ap-
proaches where nucleic acid delivery only serves as a
tool for answering scientific questions. An example for
the latter is a particular functional genomics approach
where known or unknown DNA or RNA sequences are
transfected into cells in a high throughput manner in or-
der to obtain novel screenable phenotypes (see for ex-
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Fig. 6 Transfection Kinetics and Dose-Response Profile of Standard Transfection and Magnetofection in NIH 3T3 Cells Using the
Reagents Lipofectamine and GenePorter.
The experiment was set up such as the one shown in Figure 3 with a fixed magnetic particle:DNA ratio of 2:1 (w/w), a DNA dose of
100 ng/well for the kinetics study in (A) and (B), and a serial dilution for the dose-response study in (C) and (D), and with 4 µl of Lipofecta-
mine and 5 µl of GenePorter used per µg of DNA, respectively. The experiments shown in (A) and (B) were carried out with one culture
plate each positioned upon the magnetic plate throughout the maximum incubation time of 240 minutes, one plate was kept under stan-
dard conditions. The vector formulations were removed from individual wells in triplicates each and cells in these wells were washed af-
ter 5, 10, 20, 40, and 240 minutes of incubation. The luciferase assay was carried out 20 hours after the start of the experiment. Under the
conditions tested, maximum expression was found already after 5 min with Lipofectamine, while transfection efficiency increased over
time but with a moderate slope with GenePorter (42% of the final reporter gene expression level was already achieved after 5 min). Con-
sistently, the Figures show that 10 min of magnetofection are sufficient to achieve the transfection levels obtained with the standard
reagent using 4 hours of transfection. At any time point, GenePorter formulations were more efficient than Lipofectamine formulations.
Fig. 7 Reporter Gene Expression Kinetics of Magnetofected
or Standard PEI-Transfected Luciferase Plasmid.
One vol. equivalent of a DNA stock solution (60 µg/ml) was mixed
with one vol. equivalent of a PEI stock solution (62.6 µg/ml, 25 kDa
branched PEI, Aldrich) or one vol. equivalent of a magnetic particle
suspension (240 µg/ml), respectively (all dilutions in 0.9% sodium
chloride). After 15 min of incubation one vol. equiv. of 0.9% sodi-
um chloride was added to the PEI-DNA complexes and one vol.
equiv. of PEI stock solution was added to the magnetic particle-
DNA complexes. After 15 min of incubation, 50 µl each (DNA dose
1 µg) of the resulting complexes were added to the cells seeded in
two 96-well plates at a densitiy of 20 000 cells/well, covered with
150 µl fresh medium (DMEM, 10% FCS). One plate was positioned
on the magnetic plate throughout the first 8 hours of incubation,
after which a medium change was performed (DMEM, 10% FCS).
During this incubation time, cells in triplicate wells each were
washed with PBS and lysed for luciferase assay after 1, 2, 4, and
8 hours of incubation and then again after 24 and 48 hours. The lu-
ciferase assay was performed as described (Finsinger et al.,
2000). The figure shows the early onset of detectable reporter
gene expression upon magnetofection which peaked after
24 hours and which was consistently higher than the one achieved
with standard transfection (enhancement of 9- to 18-fold after on-
set of reporter gene expression in the standard wells).
ample Grimm et al., 2002). On the one hand this would al-
low to assign function to a given nucleic acid sequence,
on the other hand it would allow to screen a given nucle-
ic acid pool for therapeutically useful sequences, and in a
further step to optimize such sequences in terms of a de-
sired biological effect. Whatever the goal of such an ap-
proach may be, it would require thousands of successful
transfections a day carried out in an automated manner.
Process time, material consumption (and connected
costs) and transfection efficiency represent the key bottle
necks to such strategies. It can easily be envisaged to in-
corporate the magnetofection technology in a robotic
system which would provide the solution to this technical
challenge.
Our own long-term goal is the use of magnetofection
as a tool for gene therapy, on the one hand for ex vivo ap-
proaches potentially useful in tissue engineering or for
the generation of tumor vaccines, on the other hand for
localized gene delivery in vivo with potential applications
in cardio-vascular or, again, cancer therapy. Any of these
purposes would involve the transfection of primary cells
with the major technical challenges of efficacy and of tar-
geting. Consequently, we have recently focussed our at-
tention on establishing the technique in primary cells with
reporter genes. We have shown that the association of
adenovirus with magnetic particles provides the virus
with the ability to infect cells which are non-permissive to
adenoviral gene delivery because they lack the required
virus receptor (CAR) (Scherer et al., 2002). This is impor-
tant because the absence of this receptor in natural tar-
gets of adenoviral gene therapy, such as tumors, severe-
ly limits the feasibility of conceptionally highly promising
approaches (Kim et al., 2002). Similarly, we have shown
localized adenoviral and nonviral gene delivery by mag-
netofection in vivo in blood vessels and in the gastro-in-
testinal tract (Scherer et al., 2002). Our most recent re-
sults show that nonviral magnetofection is highly efficient
in the ex vivo transfection of primary cells including hu-
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Fig. 8 Magnetofection and Standard Transfection of the Colon
Carcinoma Cell Line CT26 with the Transfection Reagent DM-
RIE-C Using Green Fluorescent Protein Gene as Reporter.
One vol. equiv. DNA stock (12 µg/ml in Optimem) was mixed with
2 vol. equiv. DMRIE-C suspension (30 µl/ml in Optimem), followed
by mixing with one vol. equiv. magnetic particles (12 µg/ml in Op-
timem) or with Optimem alone. A dilution series was prepared af-
ter 30 min of incubation. Cells (seeded in 24 well plates, supple-
mented with 200 µl/well fresh Optimem prior transfection) were
transfected by addition of 200 µl of complexes, containing DNA
doses of 600, 300 and 150 ng DNA. The culture plate was posi-
tioned on a magnetic plate during the first 15 min of incubation,
which was continued for a total of 5 hours. Then the medium was
exchanged for RPMI1640 medium containing 10% FCS. Fluores-
cence images were taken 24 hours after complex addition. The
Figure shows the strong improvement in percentage of transfect-
ed cells which is particularly apparent at the lower DNA doses.
Magnetofection of 150 ng DNA resulted in higher efficiency than
with 600 ng DNA in standard vector formulation.
Fig. 9 Magnetofection and Standard Transfection of Anti-
sense Oligonucleotides in HUVECs.
Cy3-labeled anti-SHP-1 phosphorothioate oligodeoxynucleo-
tides (ODN) were transfected using Effectene in combination
with magnetofection. Antisense-ODN (200 ng per well of a 24-
well plate, ca. 60 nM) were mixed with buffer EC (volume added to
result in a final volume of 30 µl after step (1), Effectene enhancer
solution (w/v ratio of 8) and magnetic particles (B) (1 mg/ml sus-
pension; w/w ratio of 1) or water only (A), vortexed for 1 second,
and incubated for 2 – 5 minutes (step 1). Then, Effectene (w/v
ratio of 20) was added, followed by vortexing for 10 seconds and
incubation for 5 – 10 minutes, and terminated by addition of
medium 199 supplemented with 20% NBCS and antibiotics (HU-
VEC medium) to a final volume of 200 µl (transfection mixture).
Before addition of the transfection mixture (200 µl each) to con-
fluent HUVEC, the cells were washed once with phosphate
buffered saline (PBS) and supplemented with 200 µl of HUVEC
medium. The culture plates were positioned on magnetic plates
for 15 minutes, followed by washing the cells 3 times with PBS
and continued cultivation in medium for 2 hours. Images were
taken using an inverted laser scanning microscope (LSM 410,
Zeiss, Jena, Germany). (A) Standard transfection; (B) magneto-
man umbilical vein endothelial cells (HUVEC), porcine
aortic endothelial cells (PAEC) (Krötz et al., unpublished
results), rat carotid artery smooth muscle cells, explanted
porcine veins, porcine and rabbit articular chondrocytes,
human and porcine airway epithelial cells, intact porcine
tracheal airway epithelium, and human keratinocytes (un-
published results). We were also successful in applying
magnetic particle-DNA complexes as aerosol directly on
human airway epithelial cells in culture with subsequent
efficient transfection by magnetic field influence, giving a
novel perspective to gene delivery to the lungs via the
airways (J. Rosenecker, unpublished results).
We have used magnetofection with great success not
only for the delivery of viruses and plasmid DNA but also
for the delivery of antisense oligonucleotides (Krötz et al.,
2003). The goal of this study was to define the role of the
p22phox subunit of endothelial NAD(P)H-oxidase in super-
oxide production in primary endothelial cells by an anti-
sense knock-out approach. Measuring such a sensitive
cellular function required that the oligonucleotide was
delivered at low dose, rapidly, and that a high percentage
of the target cells (HUVEC) were transfected. We found
that by magnetofection, oligonucleotides, applied at low
dose, became associated within minutes with up to
100% of the target cells (Figure 9), and were then rapidly
internalized and accumulated in the nuclei. This resulted
in the efficient knock-out of the target which then allowed
us to demonstrate the important role of the p22phox sub-
unit of endothelial NAD(P)H-oxidase in the enzyme’s
basal activity. Conventional transfection was associated
with significant toxicity as it either required a high vector
dose and/or long incubation times (24 hours) to yield the
required efficiency. However, when measuring sensitive
physiological functions such as superoxide production,
the scientific question itself is incompatible with transfec-
tion-associated toxicity as it would have a direct impact
on the cellular function to be measured. In the same
study (Krötz et al., 2003) we demonstrated the general
applicability of antisense magnetofection with two addi-
tional independent targets of antisense knock-out (con-
nexin 37 and cytosolic phosphatase SHP-1; data not
shown here). Finally, we also demonstrated the feasibility
of magnetic field-guided oligonucleotide targeting to
blood vessels in vivo which in the future will allow the ex-
amination of gene function directly in vivo with having the
untreated control blood vessels in the same animal (data
not shown).
Conclusions and Outlook
During the last fifteen years we have witnessed the de-
velopment of highly efficient tools for gene delivery to eu-
karyotic cells and more recently also their successful use
in gene therapy (Aiuti et al., 2002a,b; Fischer et al., 2002).
Despite these impressive achievements it may take addi-
tional decades until gene therapy becomes a broadly ap-
plicable therapeutic modality, particularly considering the
many unknown factors and risks associated with any
novel form of treatment. But this apparent delay with re-
spect to original expectations is also due to unmet tech-
nical requirements, among other things relating to gene
vector efficacy, safety and economic feasibility of its pro-
duction and handling. Although the technique of mag-
netofection is far from providing a single general solution
to these deficiencies, it opens a novel perspective on this
stony path. First of all, it provides a technical solution for
the rapid and efficient introduction of nucleic acids into
primary cells which will greatly facilitate and accelerate
the examination of gene function, the identification of nu-
cleic acids with therapeutic potential and also the as-
sessment of risks associated with the transfer of genetic
material into cells. Secondly, the technique can become
an option for in vivo targeting combined with improved
efficacy of gene delivery, potentially in combination with
other physical techniques, if appropriate magnetic fields
can be generated. As mentioned before, the essential
physical parameters governing the force acting on mag-
netic particles in liquid suspension are the magnetic flux
density, the magnetic field gradient and the particle vol-
ume. Optimizing these parameters for biomedical appli-
cations raises several demanding engineering challenges
in this exciting field of interdisciplinary research.
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